Precision manufacturing group Prime Industries has raised Rs 11.86 crore from Omega Seiki Mobility founder Dr Uday Narang, capital that will fund an R&D and incubation centre for defence, nuclear and advanced manufacturing.
Drivn's Indian subsidiary has raised Rs 45 crore from climate-focused investor Avaana Capital, extending a wave of institutional capital into India's clean mobility and fleet-electrification sector.
Indian fintech BharatPe has raised Rs 135 crore ($1.55 million) in debt financing from InnoVen Capital, Neo Group and Alteria Capital, a move that signals lenders' continued confidence in the merchant-payments company's balance sheet at a mature stage of its growth.
Digital lending platform Moneyview has set its IPO price band at Rs 32–34 per share, aiming to raise approximately Rs 1,092 crore, with subscription opening September 24 as India's fintech listing wave continues.
Tiles and bathware manufacturer Varmora Granito opened its Rs 708.02 crore initial public offering on September 22, priced between Rs 140 and Rs 148 per share, joining a crowded pipeline of mainboard listings this quarter.
The National Stock Exchange's roughly $2.3 billion initial public offering closed oversubscribed 5.71 times, pulling in more than $10 billion in bids and cementing it as India's largest listing since Hyundai Motor India in 2024.
Indian equities snapped their longest weekly losing run in six years on September 21, with the Sensex adding 564 points and the Nifty closing above 23,400 as Brent crude eased and bargain buying returned to heavyweight stocks.
September 16, 2026 emerged as one of the busiest biotech venture-financing days of the year, with Circle Pharma and Sling Therapeutics alone raising over $215 million combined, according to Fierce Biotech's 2026 fundraising tracker.
Indian startups have raised $16.3 billion across approximately 1,450 equity funding rounds so far in 2026, a 6.9% increase over the same period last year, according to Tracxn data, even as overall deal count has declined.
RegCell, an Emeryville-based biotechnology company developing therapies to restore immune tolerance, has raised $66 million in total funding, including a $44 million Series A and a non-dilutive grant from Japan's AMED.